please answer 1-4 id greatly apprentice it You are the CEO of a small pharmaceutical company. It has 55 employees and ha

[answerhappygod]

please answer 1-4 id greatly apprentice it
You are the CEO of a small pharmaceutical company. It
has 55 employees and has been in business for nearly 12 years. It
has no products on the market, so its resources, space, and capital
are extremely limited. However, it is developing an experimental
medication that shows great promise. The drug though is still about
two-and-a-half years away from the FDA’s approval for public
use.Recently, the doctors of a very sick patient have requested to
use the unap-proved and experimental drug under the FDA’s
compassionate-use regulation. Ex-panded access, also called
compassionate use, is “the use of an investigational drug outside
of a clinical trial to treat a patient with a serious or
immediately life-threatening disease or condition who has no
comparable or satisfactory alternative treatment op-tions” (FDA
2014). The patient is seven years old and has a severe viral
infection that threatens to damage his kidneys. He has had multiple
bouts of cancer, one of which required a bone marrow transplant.
His father says that the patient will die without the drug. Using
social media, his parents have enlisted the public’s help, asking
supporters to e-mail and call your company to compel you to approve
the doctors’ compassionate use request. Moreover, major television
news stations and national newspapers have picked up the story. You
have already received thousands of e-mails and calls. You and the
rest of senior management have been discussing several issues. The
company has already denied hundreds of similar requests in the
past. Provid-ing the drug (while it is still being tested) to one
patient now could mean having to provide it to other patients in
the near future. Simultaneously providing and testing
the drug is too much of an operational burden and will
overwhelm your company’s resources. Additionally, the resources the
company needs to earn FDA approval will be drained. Taking this
action may prevent your company from getting the drug to market,
eliminating the drug’s ability to help many more patients in the
future. You ask yourselves, “What is the right thing to
do
a.What ethical principles are involved in this
situation?
b.How do these ethical principles come into
conflict?
c.What nonmoral concerns do you face in this
situation?
d.Should you provide the drug for the young
patient